National Pension Service Has $45.33 Million Holdings in West Pharmaceutical Services, Inc. $WST

National Pension Service grew its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 3,080.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 126,271 shares of the medical instruments supplier’s stock after acquiring an additional 122,301 shares during the quarter. National Pension Service owned about 0.18% of West Pharmaceutical Services worth $45,331,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of WST. Bank of Nova Scotia lifted its stake in shares of West Pharmaceutical Services by 337.8% in the first quarter. Bank of Nova Scotia now owns 65,323 shares of the medical instruments supplier’s stock valued at $16,373,000 after buying an additional 50,402 shares in the last quarter. Hsbc Holdings PLC increased its position in shares of West Pharmaceutical Services by 23.3% during the fourth quarter. Hsbc Holdings PLC now owns 146,872 shares of the medical instruments supplier’s stock worth $40,425,000 after acquiring an additional 27,745 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of West Pharmaceutical Services by 100.2% in the 1st quarter. Renaissance Technologies LLC now owns 209,660 shares of the medical instruments supplier’s stock worth $52,549,000 after acquiring an additional 104,924 shares during the last quarter. Conestoga Capital Advisors LLC raised its holdings in shares of West Pharmaceutical Services by 6.7% in the 1st quarter. Conestoga Capital Advisors LLC now owns 130,970 shares of the medical instruments supplier’s stock worth $32,826,000 after acquiring an additional 8,179 shares during the last quarter. Finally, Ilmarinen Mutual Pension Insurance Co bought a new position in West Pharmaceutical Services in the 4th quarter valued at about $3,027,000. 93.90% of the stock is owned by institutional investors and hedge funds.

Insider Activity at West Pharmaceutical Services

In related news, VP Annette Favorite sold 8,135 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $340.81, for a total transaction of $2,772,489.35. Following the completion of the sale, the vice president directly owned 16,845 shares of the company’s stock, valued at approximately $5,740,944.45. This trade represents a 32.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on WST. Stephens reiterated an “overweight” rating and set a $360.00 price target on shares of West Pharmaceutical Services in a research note on Tuesday, June 2nd. Zacks Research downgraded West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. UBS Group raised their target price on West Pharmaceutical Services from $340.00 to $415.00 and gave the company a “buy” rating in a report on Wednesday. Barclays raised West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $310.00 to $400.00 in a research report on Tuesday, June 9th. Finally, Evercore reissued an “outperform” rating and issued a $425.00 price target on shares of West Pharmaceutical Services in a research report on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $373.85.

West Pharmaceutical Services Stock Up 0.4%

West Pharmaceutical Services stock opened at $345.49 on Friday. West Pharmaceutical Services, Inc. has a fifty-two week low of $223.83 and a fifty-two week high of $386.00. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. The firm’s 50-day simple moving average is $348.46 and its 200 day simple moving average is $310.28. The stock has a market cap of $24.32 billion, a PE ratio of 44.24, a price-to-earnings-growth ratio of 2.42 and a beta of 1.14.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, beating the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The firm had revenue of $872.30 million during the quarter, compared to analyst estimates of $839.98 million. During the same quarter last year, the business posted $1.84 EPS. The company’s revenue for the quarter was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Research analysts predict that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend was Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 11.27%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc (NYSE: WST) develops and manufactures components and systems used to package, contain and deliver injectable medicines and other healthcare products. Its customers include pharmaceutical, biotechnology and medical device companies, which use West products in drug administration and medical applications.

The company’s offerings include elastomer components such as stoppers, plungers and seals; syringe and cartridge components; vial and container closure systems; and specialized delivery systems for injectable and other complex medicines.